Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Three patient deaths linked to gene therapies developed by Sarepta Therapeutics (SRPT) have drawn FDA scrutiny on the viral ...

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 22.9% in the afternoon session after the ...

Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) fell 3.7% in the morning session after the company ...

What Happened? Shares of life sciences company Revvity (NYSE:RVTY) fell 7.6% in the afternoon session after the company ...

The FDA is still on track to meet its user fee targets despite a higher-than-normal vacancy rate among scientific reviewers.

The Motley Fool. DATE Tuesday, July 22, 2025 at 8:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL PARTICIPANTS President and ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.